Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.

Tan X, Furio L, Reboud-Ravaux M, Villoutreix BO, Hovnanian A, El Amri C.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51. doi: 10.1016/j.bmcl.2013.06.039. Epub 2013 Jun 24.

PMID:
23849879
2.

Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.

Tan X, Bertonati C, Qin L, Furio L, El Amri C, Hovnanian A, Reboud-Ravaux M, Villoutreix BO.

Eur J Med Chem. 2013;70:661-8. doi: 10.1016/j.ejmech.2013.10.040. Epub 2013 Oct 22.

PMID:
24211642
3.

Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.

Tan X, Soualmia F, Furio L, Renard JF, Kempen I, Qin L, Pagano M, Pirotte B, El Amri C, Hovnanian A, Reboud-Ravaux M.

J Med Chem. 2015 Jan 22;58(2):598-612. doi: 10.1021/jm500988d. Epub 2014 Dec 22.

PMID:
25489658
4.

Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).

Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A.

Biol Chem. 2005 Nov;386(11):1173-84.

PMID:
16307483
5.

Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.

Meyer-Hoffert U, Wu Z, Schröder JM.

PLoS One. 2009;4(2):e4372. doi: 10.1371/journal.pone.0004372. Epub 2009 Feb 3.

6.

hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.

Egelrud T, Brattsand M, Kreutzmann P, Walden M, Vitzithum K, Marx UC, Forssmann WG, Mägert HJ.

Br J Dermatol. 2005 Dec;153(6):1200-3.

PMID:
16307658
7.

A proteolytic cascade of kallikreins in the stratum corneum.

Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T.

J Invest Dermatol. 2005 Jan;124(1):198-203.

8.

LEKTI-1 in sickness and in health.

Roelandt T, Thys B, Heughebaert C, De Vroede A, De Paepe K, Roseeuw D, Rombaut B, Hachem JP.

Int J Cosmet Sci. 2009 Aug;31(4):247-54. doi: 10.1111/j.1468-2494.2009.00516.x. Epub 2009 May 13. Review.

9.

Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.

Sales KU, Masedunskas A, Bey AL, Rasmussen AL, Weigert R, List K, Szabo R, Overbeek PA, Bugge TH.

Nat Genet. 2010 Aug;42(8):676-83. doi: 10.1038/ng.629. Epub 2010 Jul 25.

10.

Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.

Furio L, Hovnanian A.

Biol Chem. 2014 Sep;395(9):945-58. doi: 10.1515/hsz-2014-0137. Review.

PMID:
25153381
11.

Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.

Fortugno P, Bresciani A, Paolini C, Pazzagli C, El Hachem M, D'Alessio M, Zambruno G.

J Invest Dermatol. 2011 Nov;131(11):2223-32. doi: 10.1038/jid.2011.174. Epub 2011 Jun 23.

12.

Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site.

Nunes VA, Gozzo AJ, Sampaio MU, Juliano MA, Sampaio CA, Araujo MS.

J Protein Chem. 2003 Aug;22(6):533-41.

PMID:
14703987
13.

Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.

Meyer-Hoffert U, Wu Z, Kantyka T, Fischer J, Latendorf T, Hansmann B, Bartels J, He Y, Gläser R, Schröder JM.

J Biol Chem. 2010 Oct 15;285(42):32174-81. doi: 10.1074/jbc.M109.091850. Epub 2010 Jul 28.

14.

Selective inhibitors of plasma kallikrein.

Evans DM, Jones DM, Pitt GR, Sueiras-Diaz J, Horton J, Ashworth D, Olsson H, Szelke M.

Immunopharmacology. 1996 May;32(1-3):115-6.

PMID:
8796284
15.

LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.

Bitoun E, Micheloni A, Lamant L, Bonnart C, Tartaglia-Polcini A, Cobbold C, Al Saati T, Mariotti F, Mazereeuw-Hautier J, Boralevi F, Hohl D, Harper J, Bodemer C, D'Alessio M, Hovnanian A.

Hum Mol Genet. 2003 Oct 1;12(19):2417-30. Epub 2003 Jul 29.

PMID:
12915442
16.

Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender.

Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, Takehara K, Diamandis EP.

J Invest Dermatol. 2005 Dec;125(6):1182-9.

17.

The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome.

Bennett K, Heywood W, Di WL, Harper J, Clayman GL, Jayakumar A, Callard R, Mills K.

J Proteomics. 2012 Jul 16;75(13):3925-37. doi: 10.1016/j.jprot.2012.04.045. Epub 2012 May 12.

PMID:
22588119
18.

Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.

Nin M, Katoh N, Kokura S, Handa O, Yoshikawa T, Kishimoto S.

J Dermatol Sci. 2009 Apr;54(1):17-24. doi: 10.1016/j.jdermsci.2008.11.004. Epub 2008 Dec 31.

PMID:
19118981
19.

Human tissue kallikrein gene family: applications in cancer.

Obiezu CV, Diamandis EP.

Cancer Lett. 2005 Jun 16;224(1):1-22. Review.

PMID:
15911097
20.

Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.

Pardin C, Roy I, Lubell WD, Keillor JW.

Chem Biol Drug Des. 2008 Sep;72(3):189-96. doi: 10.1111/j.1747-0285.2008.00696.x. Epub 2008 Aug 19.

PMID:
18715232

Supplemental Content

Support Center